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Background
Antidepressants are currently the mainstay of treatment
for depression; however, almost two thirds of patients
will fail to achieve remission with initial treatment. Evi-
dence has shown that adjunctive therapy with atypical
antipsychotics has the potential for beneficial anti-
depressant effects in the absence of psychotic symptoms
[1].
Materials and methods
Using a sample of 100 patients with MDD who have
been visited in Barcelona’s Sant Martí Sud outpatient
mental health center during the year 2008, sociodemo-
graphical (gender, age) and clinical data (toxic consume,
psychiatric background, use of antipsychotics) are ana-
lysed with SPSS 15.0 statistical package
Results
Antipsychotics are used in 27% of the patients, with a
predominancy in the female gender (77.8%), a global
average age of 57.9 ± 12.6 years. There is a predomi-
nancy of absence of psychiatric background (55.6%) and
the absence of previous hospitalisations (66.7%). In
96.3% of the sample there was no toxic abuse.
It is observed the following distribution in the use of
antipsychotics: quetiapine and olanzapine (29.6% each
one), risperidone (26%), paliperidone (3%). Average dose
was 5.7 mg/d for olanzapine, 2.3 mg/d for risperidone,
84.5 mg/d for quetiapine and 6 mg/d for paliperidone.
Conclusions
It is observed an important frequency in the use of anti-
psychotic treatment for MDD, in relation with the fact
that there is growing evidence for the efficacy of atypical
antipsychotics for adjunctive treatment of depressive
symptoms of MDD. There is scientific evidence that
supports the use of the two antipsychotics predomi-
nantly used in our sample (olanzapine and quetiapine)
[2], but more studies are needed to establish its place in
management.
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